Default company panoramic image

Cellanyx Diagnostics

Harnessing predictive biomarkers enabled by microfluidics, Cellanyx predicts which "low-risk" patients are actually at risk of local and/or metastatic disease

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded January 2013
  • Employees 8
  • Website

Company Summary

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making in cancer patients. The company’s unique ‘biopsy-on-a-chip’ provides quantitative and actionable, predictors of tumor aggressiveness, metastatic potential and adverse pathology based on multiple proprietary biomarkers from tumors. Cellanyx has demonstrated clinical proof-of-concept in prostate cancer.


  • Default avatar
    Ashok Chander
    Chief Executive Officer, Founder

    SB, MIT; PhD, Columbia University

  • Default avatar
    Jonathan Varsanik
    VP Engineering

    SB, MIT; PhD, MIT

  • Default avatar
    Michael Manak
    VP Research & Development

    PhD, University of Florida; Post Doctoral Fellow, Harvard Medical School

  • Default avatar
    Brad Hogan
    Director of Biological Integration

    BS, Marquette University; PhD, Boston University

  • 6801fb7c 4c1b 4802 8211 839d6a4f4cc0
    VP of Commercialization

    BS, UMN

  • Default avatar
    Nikhil Joshi
    Marketing Lead

    BS, University of California, San Diego; MS, Columbia University